Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc (MDT) is a global leader in medical technology, developing innovative healthcare solutions that address chronic diseases and complex conditions. This dedicated news hub provides investors and professionals with timely updates on the company's strategic initiatives, regulatory milestones, and technological breakthroughs.
Access authoritative information spanning earnings announcements, product approvals, partnership developments, and clinical trial outcomes. Our curated collection ensures you stay informed about MDT's advancements in cardiac care, neuromodulation, diabetes management, and surgical robotics.
Discover press releases detailing regulatory submissions, executive appointments, and global market expansions. Each update is verified for accuracy, offering insights into how Medtronic maintains its position at the forefront of medical innovation while navigating evolving healthcare landscapes.
Bookmark this page for direct access to primary source materials and analysis-free reporting on MDT's operational developments. Regular updates ensure you never miss critical information impacting the medical technology sector.
Medtronic (NYSE:MDT) has received FDA approval for its Altaviva™ device, a minimally invasive implantable tibial neuromodulation (ITNM) therapy for treating urge urinary incontinence. The device, implanted near the ankle without sedation or imaging, helps restore bladder-brain communication through electrical impulses to the tibial nerve.
The Altaviva device features a 15-year battery life, automatic therapy delivery, and MRI compatibility. It is designed to address a significant market, with 16 million Americans affected by urge urinary incontinence. This approval positions Medtronic as the only company offering a complete portfolio of neuromodulation therapies for bladder control issues.
Medtronic (NYSE:MDT) has announced the pricing of €1.5 billion in senior notes through its subsidiary Medtronic, Inc. The offering consists of €750 million of 2.950% senior notes due 2030 and €750 million of 4.200% senior notes due 2045.
The notes will be fully guaranteed by Medtronic plc and Medtronic Global Holdings S.C.A. The proceeds will be used to repay Medtronic Luxco's existing notes: the 0.000% Senior Notes due 2025 and 2.625% Senior Notes due 2025. The offering is expected to close on September 29, 2025, with Deutsche Bank AG and Goldman Sachs serving as joint book-running managers.
Medtronic (NYSE:MDT) has launched ELEVATE-HFpEF, a global pivotal study investigating a novel cardiac pacing treatment for patients with Heart Failure with preserved Ejection Fraction (HFpEF). The study will evaluate whether personalized elevated pacing rates using conduction system pacing can improve outcomes for HFpEF patients.
The trial will enroll up to 700 participants across multiple regions, using Medtronic's commercially available pacemaker and SelectSecure™ MRI SureScan™ Model 3830 pacing leads. The study targets HFpEF, which affects 32 million people worldwide and represents approximately 50% of heart failure cases. Participants will be followed for one year to assess the efficacy and safety of this investigative treatment.
Medtronic (NYSE:MDT) announced positive results from the Enable Hernia Repair clinical study evaluating their Hugo™ robotic-assisted surgery (RAS) system. The study, involving 193 patients, is the first-ever IDE clinical study for robotic-assisted hernia surgery in the U.S.
The study achieved remarkable results, with a 100% surgical success rate, exceeding the 85% performance goal. Safety endpoints were met with a 0.0% surgical site event rate for inguinal repairs and 2.1% for ventral repairs, both significantly below the 30% threshold. Mean hospital stays were brief at 4.7 hours for inguinal and 6.7 hours for ventral procedures.
The Hugo RAS system is currently available in 30+ countries across five continents, with FDA review ongoing for urology indication and planned expansions into hernia repair and gynecology.
Medtronic (NYSE:MDT) announced two significant FDA milestones for its MiniMed™ 780G system: clearance of the SmartGuard™ algorithm for integration with Abbott's Instinct sensor in type 1 diabetes, and approval for use in adults with type 2 diabetes.
The integration with Abbott's Instinct sensor, the world's smallest and thinnest integrated CGM with a 15-day wear time, will be available after compliance documentation completion. In clinical trials for type 2 diabetes patients, the system demonstrated impressive results, including a 0.7% reduction in HbA1c and increased Time in Range to 81% from 72%.
The MiniMed™ 780G becomes the first and only automated insulin delivery system with Meal Detection™ technology available for type 2 diabetes patients, marking a significant advancement in diabetes management technology.
Medtronic plc (NYSE:MDT), a global healthcare technology leader, has announced its participation in four major investor conferences in September 2025. Key executives, including Chairman and CEO Geoff Martha and CFO Thierry Piéton, will represent the company at the Wells Fargo Healthcare Conference, Morgan Stanley Global Healthcare Conference, Deutsche Bank Healthcare Summit, and BofA Global Research Healthcare Conference.
The company, headquartered in Galway, Ireland, serves over 150 countries with a team of 95,000+ employees. Medtronic's technologies address 70 health conditions, including cardiac devices, surgical robotics, insulin pumps, and patient monitoring systems. Live webcasts of all conference sessions will be available through the company's investor relations website.
Medtronic (NYSE:MDT) has announced significant governance changes and strategic initiatives aimed at enhancing shareholder value. The company has appointed two new independent directors to its Board: John Groetelaars and Bill Jellison, both bringing extensive medical technology industry experience.
The Board has established two new special committees: a Growth Committee focusing on M&A, R&D investments, and potential divestitures (including the planned Diabetes business separation), and an Operating Committee dedicated to optimizing operational performance and margin expansion. These initiatives follow constructive engagement with Elliott Investment Management, one of Medtronic's largest investors.
The company plans to host an Investor Day in mid-2026 to discuss strategic priorities and financial objectives.
Medtronic (NYSE:MDT) reported strong Q1 FY2026 results with revenue reaching $8.6 billion, an 8.4% increase as reported and 4.8% organic growth. The company achieved GAAP diluted EPS of $0.81 (up 1%) and non-GAAP diluted EPS of $1.26 (up 2%).
Key performance highlights include Cardiac Ablation Solutions revenue surge of nearly 50% (72% in US) driven by pulsed field ablation products. The Cardiovascular Portfolio led growth with a 7.0% organic increase, while the Diabetes business showed strong performance with 7.9% organic growth.
Looking ahead, Medtronic raised its FY26 EPS guidance to $5.60-$5.66 (previously $5.50-$5.60) while maintaining organic revenue growth guidance of approximately 5%. The company expects reduced tariff impact of approximately $185 million, down from the previous estimate of $200-350 million.
Medtronic (NYSE:MDT) has declared a quarterly cash dividend of $0.71 per ordinary share for the second quarter of fiscal year 2026. The dividend will be paid on October 17, 2025, to shareholders of record as of September 26, 2025.
This declaration maintains the dividend level announced in May 2025. As a member of the S&P 500 Dividend Aristocrats index, Medtronic has consistently increased its annual dividend for 48 consecutive years. The company operates globally with 95,000+ employees across 150+ countries, focusing on healthcare technology solutions that address 70 different health conditions.
Medtronic (NYSE:MDT), the global healthcare technology leader, has scheduled its fiscal year 2026 first quarter financial results announcement for Tuesday, August 19, 2025. The results will cover the period ending July 25, 2025.
The company will release its financial summary at 5:45 a.m. CDT, followed by a video webcast at 7:00 a.m. CDT. Medtronic has also announced the reporting dates for the remaining quarters of FY2026: November 18, 2025 (Q2), February 17, 2026 (Q3), and May 20, 2026 (Q4).
FAQ
What is the current stock price of Medtronic (MDT)?
What is the market cap of Medtronic (MDT)?
